Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460

Clin Cancer Res. 2002 Feb;8(2):596-606.

Abstract

Purpose: Here we report on the role of mitochondria, death receptors (DRs), and caspases in exerting the cytotoxic effect of clinically relevant concentrations of paclitaxel in the non-small cell lung cancer cell line NCI-H460.

Experimental design: We have characterized paclitaxel-induced cell death with annexin V, propidium iodide staining, and poly(ADP-ribose) polymerase cleavage assays. The involvement of the mitochondria pathway was studied by monitoring cytochrome c release and using H460 cells stable in overexpressing Bcl-2 or Bcl-x(L). DR dependency was analyzed in FADD dominant-negative or cytokine response modifier A-overexpressing cells, and a possible role for DR4 and DR5 was investigated by antagonistic antibodies. Caspase activity and cleavage assays and treatment with the synthetic inhibitor zVAD-fmk were used to determine the involvement of caspases.

Results: Paclitaxel-treated cells displayed several features of apoptosis, including annexin V staining and poly(ADP-ribose) polymerase cleavage. The sequence of events suggested the involvement of a DR, as indicated by an early role for Fas-associated death domain and caspase-8, followed by cleavage of Bid and the disruption of mitochondria; nonetheless, we failed to demonstrate the involvement of DR4 and DR5. Interestingly, inhibition of either one of these routes only resulted in a 30% reduction of cell death that was in line with the observed small effect of caspase inhibition by zVAD-fmk on H460 cell survival.

Conclusion: Paclitaxel triggers cell death in H460 cells mainly via a currently unidentified caspase-independent mechanism in which the basic apoptotic machinery is merely coactivated. This finding is in sharp contrast with the largely caspase-dependent response elicited by DNA-damaging agents in these cells. We speculate on therapeutic implications.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Chloromethyl Ketones / pharmacology
  • Annexin A5 / pharmacology
  • Antineoplastic Agents, Phytogenic / pharmacology
  • Apoptosis
  • Arabidopsis Proteins*
  • Blotting, Western
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Caspase 8
  • Caspase 9
  • Caspases / metabolism
  • Caspases / pharmacology*
  • Cell Death
  • Cell Line
  • Cell Survival
  • Cytochrome c Group / metabolism
  • Cytosol / metabolism
  • DNA Damage
  • Electrophoresis, Polyacrylamide Gel
  • Enzyme Activation
  • Enzyme Inhibitors / pharmacology
  • Fatty Acid Desaturases / genetics
  • Genes, Dominant
  • Humans
  • Lung Neoplasms / drug therapy*
  • Mitochondria / metabolism
  • Models, Biological
  • Paclitaxel / pharmacology*
  • Poly(ADP-ribose) Polymerases / metabolism
  • Propidium / pharmacology
  • Protein Structure, Tertiary
  • Receptors, TNF-Related Apoptosis-Inducing Ligand
  • Receptors, Tumor Necrosis Factor / metabolism
  • Spectrometry, Fluorescence
  • Time Factors
  • Transfection
  • Tumor Cells, Cultured

Substances

  • Amino Acid Chloromethyl Ketones
  • Annexin A5
  • Antineoplastic Agents, Phytogenic
  • Arabidopsis Proteins
  • Cytochrome c Group
  • Enzyme Inhibitors
  • Receptors, TNF-Related Apoptosis-Inducing Ligand
  • Receptors, Tumor Necrosis Factor
  • TNFRSF10A protein, human
  • TNFRSF10B protein, human
  • benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
  • Propidium
  • Fatty Acid Desaturases
  • Fad7 protein, Arabidopsis
  • Poly(ADP-ribose) Polymerases
  • CASP8 protein, human
  • CASP9 protein, human
  • Caspase 8
  • Caspase 9
  • Caspases
  • Paclitaxel